Xaira Therapeutics is an integrated biotechnology company applying AI to drug discovery and development. It combines machine learning research, large-scale biological data generation, and therapeutic product development to create new medicines.
Access to pre-IPO shares is available to accredited investors through UpMarket.
Latest Price
$2.7B
Series A, Apr 2024, Perplexity
UpMarket Estimate
$2.7B
Based on UpMarket valuation model
How to Invest in Xaira Therapeutics Through UpMarket
Xaira Therapeutics shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.
Step 01
Verify accredited investor status
Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.
Step 02
Create an UpMarket account
Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.
Step 03
Review available Xaira Therapeutics offerings
Full offering memoranda and risk disclosures provided before any commitment is required.
Step 04
Complete subscription documents
Review and sign subscription agreement. All documents handled digitally through the platform.
Step 05
Fund your investment
Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
$1.3B+
UpMarket has brokered over $1.3 billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through March 31, 2026. Of the total, approximately $301 million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.
Valuation Growth Over Time
Post-money valuation by round
Previous roundsMost recent
Date
Round
PPS (split-adj.)
Valuation
Apr 2024
Series A
$2.7B
Why Investors Are Watching Xaira Therapeutics
Growth Signal
Xaira launched with $1B to scale AI drug discovery
Xaira emerged in 2024 with a $1 billion funding round, one of the largest private healthcare financings in recent memory. The capital was backed by Arch Venture Partners and Foresite Capital, signaling room to hire, build data, and advance multiple programs.
Competitive Moat
Three-part platform combines ML, data, and therapeutics
Xaira says its model is built around advanced machine learning research, expansive data generation, and robust therapeutic product development. The company also describes an end-to-end approach aimed at discoveries optimized for human biology.
Team & Talent
Xaira is adding leadership and moving to South San Francisco
Xaira is bolstering its leadership team while relocating to the Gateway of Pacific III campus in South San Francisco. The move and hiring push are designed to support its AI-powered drug discovery ambitions after a blockbuster funding round.
Interested in Xaira Therapeutics stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.
UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
Strategy, fees & legal reviewed in full
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers — legal counsel, auditor, administrator, and custodian.
Disciplined managers only
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Built around your objectives
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. As of March 2026, Xaira Therapeutics is a private company and does not trade on any public stock exchange. Accredited investors can access Xaira Therapeutics shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.
Xaira Therapeutics does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.
Yes. Accredited investors can indicate interest in Xaira Therapeutics shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered more than $500M in alternative investments since 2019.
Pre-IPO investments carry significant risks. Xaira Therapeutics shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.
The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.
UpMarket's valuation estimate of is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.
Xaira Therapeutics is an integrated biotechnology company applying AI to drug discovery and development, valued at $2.7B after launching with more than $1B to scale its platform — accredited investors can access Xaira Therapeutics stock through UpMarket.